Eli Lilly And Co LLY experienced a 1.37% increase in pre-market trading on Wednesday, as per Benzinga Pro. This uptick occurs as the company gears up to announce its third-quarter earnings. Wall ...

A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years For the past ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55 ...

We’re living in a world full of foods that trigger constant hunger, cravings and thoughts about eating. Is it even possible ...

Mounjaro was launched in mid-2022, while Zepbound was launched in November 2023. Despite a short time on the market, Mounjaro and Zepbound have become key top-line drivers for Lilly, as they are ...

Shares are up more than 50% already this year, as the story surrounding the company’s GLP-1 drugs gets better and better.

Qsymia’s manufacturer also released postmarketing data showing the oral therapy for weight loss was associated with ...

Pfizer (PFE) offered up some more details on its weight loss drug pipeline on Tuesday during a call with investors after it ...

Get the latest updates on Amgen's upcoming Q3 earnings results, including insights from analysts on key products and trial data expectations.

智通财经APP获悉，今年以来，在减肥药这一全球范围的新兴领域，丹麦医药巨头诺和诺德公司(NVO.US)在成为“股票市场减肥药大赢家”的竞争中落后于美国医药巨头礼来(LLY.US)，其股价涨势目前大幅跑输于礼来。但不少分析师预计，随着诺和诺德与礼来财报 ...